P

PIRCHER C. C.

Last name: PIRCHER C. C.

2021 (v1)

Publication

Metadata-only

Beyond first-line immunotherapy: Potential therapeutic strategies based on different pattern progressions: Oligo and systemic progression

Prelaj A. Pircher C. C. Massa G.

First-line immune-checkpoint inhibitor (ICI)-based therapy has deeply changed the treatment landscape and prognosis in advanced non-small cell lung cancer (aNSCLC) patients with no targetable alterations. Nonetheless, a percentage of patients progressed on ICI as monotherapy or combinations. Open questions remain on patients' selection, the...

Uploaded on: April 14, 2023